Folate-receptor-targeted radionuclide imaging agents

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1143-1160

  Ke, Chun Yen ^a   Mathias, Carla J ^a   Green, Mark A ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Diagnostic imaging; Folate receptor; Nuclear medicine; Radiopharmaceutical

Indexed keywords

CELL CULTURE; CHELATION; DRUG PRODUCTS; RADIOISOTOPES; TUMORS;

DIAGNOSTIC IMAGING; RADIOLABELING; RADIONUCLIDE AGENTS; TUMOR IMAGING;

MEDICAL IMAGING;

CHELATE; CONTRAST MEDIUM; COPPER 64; DEFEROXAMINE; DIAMINE DERIVATIVE; FOLATE RECEPTOR; FOLIC ACID; GALLIUM; GALLIUM 66; GALLIUM 67; INDIUM 111; MEMBRANE RECEPTOR; NICOTINAMIDE DERIVATIVE; PENTETIC ACID; TECHNETIUM 99M; UNCLASSIFIED DRUG;

DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; ISOTOPE LABELING; PRIORITY JOURNAL; REVIEW; SCINTISCANNING;

EID: 16544383488     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.004     Document Type: Article

References (77)

1. Taylor A., Schuster D.M., Alazraki N. A Clinician's Guide to Nuclear Medicine. 2000;Society of Nuclear Medicine, Reston, VA.
2. Ter-Pogossian M.M., Raichle M.E., Sobel B.E. Positron emission tomography. Sci. Am. 243:1980;170-181.
3. Reivich M., Alavi A. Positron Emission Tomography. 1985;Alan R. Liss, New York.
4. Phelps M.E., Mazziotta J.C., Schelbert H.R. Positron Emission Tomography and Autoradiography. 1986;Raven Press, New York.
5. von Schulthess G.K. Clinical Positron Emission Tomography. 2000;Lippincott Williams and Wilkins, Philadelphia.
6. Wahl R.L. Principles and Practice of Positron Emission Tomography. 2002;Lippincott Williams and Wilkins, Philadelphia.
7. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L. Jr., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:1993;557-567.
8. Stein R., Goldenberg D.M., Mattes M.J. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int. J. Cancer. 47:1991;163-169.
9. Li P.Y., Del Vecchio S., Fonti R., Carriero M.V., Potena M.I., Botti G., Miotti S., Lastoria S., Menard S., Colnaghi M.I., Salvatore M. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J. Nucl. Med. 37:1996;665-672.
10. 2 fragments in ovarian carcinoma patients. Cancer Res. 53:1993;5413-5418.
11. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1997;193-198.
12. Williams W.M., Huang K.C. Renal tubular transport of folic acid and methotrexate in the monkey. Am. J. Physiol. 242:1982;F484-F490.
13. Selhub J., Franklin W.A. The folate-binding protein of rat kidney. J. Biol. Chem. 259:1984;6601-6606.
14. Selhub J., Emmanouel D., Stavropoulos T., Arnold R. Renal folate absorption and the kidney folate binding protein: I. Urinary clearance studies. Am. J. Physiol. 252:1987;F750-F756.
15. Selhub J., Nakamura S., Carone F.A. Renal folate adsorption and the kidney folate binding protein: II. Microinfusion studies. Am. J. Physiol. 252:1987;F757-F760.
16. Kamen B.A., Caston J.D. Identification of a folate binder in hog kidney. J. Biol. Chem. 250:1975;2203-2205.
17. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 52:1992;6708-6711.
18. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawsky V.R., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
19. Holm J., Hansen S.I., Hoier-Madsen M., Birn H., Helkjaer P.-E. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity. Arch. Biochem. Biophys. 366:1999;183-191.
20. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer. 73:1994;2432-2443.
21. Wu M., Gunning W., Ratnam M. Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus and cervix. Cancer Epidemiol. Biomark. Prev. 8:1999;775-782.
22. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., Bottero F., Colnaghi M.I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies Mov18 and Mov19. Eur. J. Cancer. 30A:1994;363-369.
23. + cells. Blood. 93:1999;3940-3948.
24. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;1609-1616.
25. Spinella M.J., Brigle K.E., Sierra E.E., Goldman I.D. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J. Biol. Chem. 270:1995;7842-7849.
26. Holm J., Hansen S.I., Hoier-Madsen M., Helkjaer P.-E., Bzorek M. A high-affinity soluble folate receptor in fluids of non-neoplastic ovarian cysts: radioligand binding, molecular size, hydrophobic residue, and immunological properties. APMIS. 103:1995;862-868.
27. Baggnoli M., Canevari S., Figini M., Mezzanzanica D., Raspagliesi F., Tomassetti A., Miotti S. A step further in understanding the biology if the folate receptor in ovarian carcinoma. Gynecol. Oncol. 88:2003;S140-S144.
28. Maziarz K.M., Monaco H.L., Shen F., Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors α and β J. Biol. Chem. 274:1999;11086-11091.
29. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 34:1995;5660-5665.
30. Matherly L.H., Wong S.C., Angeles S.M., Taub J.W., Smith G.K. Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumors and tissues. Proc. Am. Assoc. Cancer Res. 35:1994;307.
31. Shen F., Zheng X., Wang J., Ratnam M. Identification of amino acid residues that determine the differential ligand specificities of folate receptors α and β Biochemistry. 36:1997;6157-6163.
32. Wang H., Ross J.F., Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type γ/γ′ Nucleic Acids Res. 26:1998;2132-2142.
33. Holm J., Hansen S.I., Hoier-Madsen M., Bostad L. High-affinity folate binding in human choroid plexus. Biochem. J. 280:1991;267-271.
34. Mattes M.J., Major P.P., Goldenberg D.M., Dion A.S., Hutter R.V., Klein K.M. Patterns of antigen distribution in human carcinomas. Cancer Res. 50:1990;880S. (Suppl.).
35. Trimble E.L. The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55:1994;S1-S3.
36. Gucalp R., Dutcher J., Wiernik P.H. Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon? Semin. Nucl. Med. 27:1997;3-9.
37. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., Tumolo S., Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer (Pred. Oncol.). 79:1998;121-126.
38. Coney L.R., Tomasetti A., Carayannopoulos I., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51:1991;6125-6132.
39. Crippa F., Buraggi G.L., Dire E., Gasparini M., Seregni E., Canevari S., Gadina M., Presti M., Marini A., Seccamani E. Radioimmunoscintigraphy of ovarian cancer with the Mov18 monoclonal antibody. Eur. J. Cancer. 27:1991;724-729.
40. Molthoff C.F., Buist M.R., Kenemans P., Pinedo H.M., Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, Mov18, reactive with an ovarian cancer-associated antigen. J. Nucl. Med. 33:1992;2000-2005.
41. 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J. Nucl. Med. 41:2000;1168-1176.
42. van Zanten-Przybysz I., Molthoff C.F., Roos J.C., Verheijen R.H., van Hof A., Buist M.R., Prinssen H.M., den Hollander W., Kenemans P. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int. J. Cancer. 92:2001;106-114.
43. Kalofonos H.P., Karamouzis M.V., Epenetos A.A. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol. 40:2001;549-557.
44. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug. Chem. 7:1996;56-62.
45. Mathias C.J., Wang S., Lee R.J., Water D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1996;1003-1008.
46. 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl. Med. Biol. 26:1999;23-25.
47. 68Ga-labelled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl. Med. Biol. 30:2003;725-731.
48. Kamen B.A., Wang M.T., Streckfuss A.J., Peryea X., Anderson R.G.W. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263:1988;13602-13609.
49. Antony A.C., Kane M.A., Portillo R.M., Elwood P.C., Kolhouse J.F. Study of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate. J. Biol. Chem. 260:1985;14911-14917.
50. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5572-5576.
51. Kutsky R.J. Handbook of Vitamins, Minerals, and Hormones. 2nd ed. 1981;273 Van Nostrand Reinhold, New York.
52. 111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug. Chem. 8:1997;673-679.
53. Luo J., Smith M.D., Lantrip D.A., Wang S., Fuchs P.L. Efficient syntheses of pyrofolic acid and pteroyl azide, reagents for the production of carboxyl-differentiated derivatives of folic acid. J. Am. Chem. Soc. 119:1997;10004-10013.
54. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-Folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. 39:1998;1579-1585.
55. 111In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol. 25:1998;585-587.
56. Mathias C.J., Green M.A. Alternative kit formulations for compounding of In-111-DTPA-folate (Folatescan). J. Nucl. Med. 41:2000;S1113.
57. Mathias C.J., Waters D.J., Wang S., Low P.S., Green M.A. Indium-111-labeled indium(III)-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate receptors: the effect of tumor size on targeting selectivity and radiochemical analysis of excreted tracer. J. Labelled Compd. Radiopharm. 40:1997;365-367.
58. D.P. Trump, Synthesis and Metabolism of Radiolabeled Folate-Chelate Conjugates, PhD thesis, Purdue University, West Lafayette, IN, 2001.
59. 111In-DTPA-Folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med. 44:2003;700-707.
60. 99mTc]DTPA-Folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug. Chem. 11:2000;253-257.
61. 3-DTPA-Folate as a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol. 29:2002;569-573.
62. 99mTc-based radiopharmaceutical. Bioconjug. Chem. 13:2002;1200-1210.
63. Maecke H.R., Riesen A., Ritter W. The molecular structure of indium-DTPA. J. Nucl. Med. 30:1989;1235-1239.
64. 2O. Russ. J. Inorg. Chem. (Engl. Transl.). 40:1995;1083-1094.
65. Brechbiel M.W., Gansow O.A., Atcher R.W., Schlom J., Esteban J., Simpson D.E., Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 25:1986;2772-2781.
66. 111In-labeled folate conjugate of "octadentate-DTPA" J. Nucl. Med. 41:2000;232P.
67. 111In-DTPA conjugate of pteroic acid. J. Nucl. Med. 42:2001;114P-115P.
68. Kamen B.A., Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5983-5987.
69. +(M=Re, Tc) directed towards radiopharmaceutical application. Coord. Chem. Rev. 190-192:1999;901-919.
70. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J. Nucl. Med. 40:1999;1913-1917.
71. 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug. Chem. 11:2000;345-351.
72. 99mTc Labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99:1999;2235-2268.
73. 99mTc. Bioconjug. Chem. 8:1997;146-154.
74. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40:1999;1563-1569.
75. P.W. Wedeking, R.E. Wager, T. Arunachalam, K. Ramalingam, K.E. Linder, R.S. Ranganathan, A.D. Nunn, N. Raju, M. Tweedle, Metal complexes derivatized with folate for use in diagnostic and therapeutic applications, (2000) U.S. Patent 6093382.
76. P.W. Wedeking, R.E. Wager, T. Arunachalam, K. Ramalingam, K.E. Linder, R.S. Ranganathan, A.D. Nunn, N. Raju, M. Tweedle, Metal complexes derivatized with folate for use in diagnostic and therapeutic applications, (2001) U.S. Patent 6221334.
77. Ke C.-Y., Mathias C.J., Yang Z.-F., Luo J., Low P.S., Waters D.J., Green M.A. Synthesis and evaluation of folate-bis(thiosemicarbazone) and folate-CYCLAM conjugates for possible use as folate-receptor-targeted copper radiopharmaceuticals. J. Labelled Compd. Radiopharm. 42:1999;S821-S823.